March 20, 2019
Jennifer Barrett, Associate Editor
Daratumumab (Darzalex) in combination with lenalidomide and dexamethasone under evalution as a treatment for patients with newly-diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.


Jennifer Nessel, Assistant Editor
Combination regimen of atezolizumab and chemotherapy Abraxane approved for adults with unresectable locally-advanced or metastatic triple-negative breast cancer.
Jennifer Barrett, Associate Editor
Guselkumab (Tremfya, Janssen) is a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis.
Jennifer Barrett, Associate Editor
Trastuzumab and hyaluronidase-oysk subcutaneous injection approved for certain patients with HER2-positive early and metastatic breast cancer.
Jennifer Barrett, Associate Editor
Potential adverse effects from health interventions, such as a drug reaction or an effect of a procedure, were not fully reported in more than one-third of published health study reviews.
Jennifer Barrett, Associate Editor
Caplacizumab-yhdp treats adults with acquired thrombotic thrombocytopenic purpura, a rare and life-threatening blood clotting autoimmune disorder.  
About the Specialty Pharmacy Times Industry Guide

The Specialty Pharmacy Times Industry Guide includes comprehensive editorial content relative to all specialty pharmacy stakeholders. Content includes information relative to market trends, commercialization, distribution, order to cash, HUB Services, managed care strategies and DIR fees. The guide also includes profiles, and a complete list of stakeholders along the patient journey: specialty pharmacies, wholesaler distributors, manufacturers, support services, group purchasing, and trade associations.

Sign Up for the Industry Guide Newsletter

Copyright © 2006-2018 Pharmacy & Healthcare Communications, LLC
All Rights Reserved

About Us